Kymera Therapeutics

41 articles with Kymera Therapeutics

• Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

  1/12/2021

  Company plans Phase 1 trial initiations across three novel degrader programs by end of 2021 Initiation of the single ascending dose portion of Phase 1 trial of KT-474 in healthy volunteers anticipated in 1Q 2021 Strong financial position to support pipeline execution with opportunities to accelerate growth and broaden clinical indications

• Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

  1/5/2021

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. ET on Thursday, January 14, 2021.

• 

  BioSpace Movers & Shakers, Dec. 18

  12/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Kymera Therapeutics Announces Key Leadership Appointments

  12/16/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC) and Paul Cox as Vice President of Investor Relations and Communications. “I am excited to welcome both William and Paul to Kymera. These key strategic

• Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

  12/7/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further support development of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021. Data were presented at the virtual 62nd American Society of Hematology (AS

• Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference

  11/23/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced Nello Mainolfi, Co-Founder, President and CEO and Jared Gollob, Chief Medical Officer of Kymera Therapeutics, will present at the Piper Sandler 32nd Annual Healthcare Conference

• Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

  11/11/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the Stifel 2020 Virtual Healthcare Conference

• Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

  11/5/2020

  Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi Reported positive interim results from non-interventional study o f KT-474 (IRAK4 degrader) in HS patients and declared KT-413 (IRAKIMiD degrader) as a development candidate and initiated IND enabling activities

• Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

  11/4/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology (ASH) Annual Meeting taking place virtually from Dec. 5-8, 2020. “We are excited to share for the first time preclinical d

• Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit

  10/12/2020

  Kymera Therapeutics, Inc., a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15.

• Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa

  10/9/2020

  Results support clinicaldevelopment of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS)and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 trial on track for start in 2021

• Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

  9/14/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference at 5:00 p.m. ET on

• Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

  8/27/2020

  Kymera Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, announced the appointment of Richard Chesworth, PhD, to the role of Chief Scientific Officer.

• Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

  8/25/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the closing of its upsized initial public offering of 9,987,520 common shares, including the exercise in full by the underwriters of their option to purchase up to 1,302,720

• Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

  8/21/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, t

• Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

  7/9/2020

  Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments

• 

  Kymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 Billion

  7/9/2020

  They will focus on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such and rheumatoid arthritis.

• Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

  6/11/2020

  Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced that it will present preclinical data on its potent and highly selective STAT3 degraders as well as the first data from its novel IRAKIMiD degraders combining IRAK4 and IMiD substrate degradation.

• Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis

  6/3/2020

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced that the company has initi

• Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

  3/12/2020

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced the closing of a $102 million Series C financing.